MSI-H
Entity.
- Evidence
- 112 documents · 44 separate publishers
- Standing
- A name from our starting list; its record is kept up to date automatically from coverage
- Time
- first seen 11 Mar 2026, last seen 1 Nov 2026
- Measured
- 12% of mentions say something specific about it; the rest only name it
- As of
- 3 Nov 2026
Where this comes from
- Crc-Digest · 2026-11-01 · Final overall survival analysis of CheckMate-8HW supports nivolumab plus ipilimumab in first-line MSI-H/dMMR metastatic CRC (opens the source in a new tab)
- OncoDaily · 2026-10-25 · AZUR-1 at ESMO 2026: Dostarlimab monotherapy in dMMR/MSI-H Locally Advanced Rectal Cancer (opens the source in a new tab)
- Frontiers Precision Oncology · 2026-10-23 · Clinicopathological and molecular characteristics of second primary colorectal cancer in cancer survivors including MSI-H status and anatomical distribution (opens the source in a new tab)
- Crc-Digest · 2026-10-21 · FDA Approves Dostarlimab for MSI-H/dMMR Locally Advanced Rectal Cancer (opens the source in a new tab)
- J Immunother Cancer · 2026-10-20 · Observation versus maintenance immunotherapy after PD-1-induced clinical complete response in dMMR/MSI-H colorectal cancer managed non-operatively: a multicenter co… (opens the source in a new tab)
- J Gastrointest Cancer · 2026-10-15 · Resistance Phenotypes and Treatment Sequencing After Immune Checkpoint Blockade in MSI-H/dMMR Metastatic Colorectal Cancer: A Review. (opens the source in a new tab)
- Front Pharmacol · 2026-10-12 · WRN helicase addiction in MSI-H colorectal cancer: biomarker-guided pharmacology, resistance evolution, and implications for other gastrointestinal cancers. (opens the source in a new tab)